Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

November 16th, 2015: Aurgalys releases new analyst reports on Onxeo [Euronext:ONXEO]

novembre 25, 2015

Paris-Evry, France, November 16th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, issued new analyst report on Onxeo.

« Onxeo announced the Phase I Beleodaq + CHOP (BelCHOP) results for 1st line treatment of Peripheral T-Cell Lymphoma (PTCL). This trial was intended to determine the maximum tolerated dose of Beleodaq in combination with CHOP for a confirmatory Phase III study. The results confirmed the good tolerance profile of Beleodaq when combined with chemotherapy, at the approved dose of Beleodaq. Interestingly, the BelCHOP therapy also showed promising clinical activity with a Complete Response Rate of 72%, supporting further clinical investigation in the upcoming Phase III study (H1-2016) […] »

You can download our report (in English) at the following link:

Comments are closed.